Compare FLY & ABCL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FLY | ABCL |
|---|---|---|
| Founded | 2017 | 2012 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Military/Government/Technical | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.5B | 3.5B |
| IPO Year | 2025 | 2020 |
| Metric | FLY | ABCL |
|---|---|---|
| Price | $22.70 | $12.61 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 5 |
| Target Price | ★ $38.88 | $8.40 |
| AVG Volume (30 Days) | 2.2M | ★ 4.4M |
| Earning Date | 05-04-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 76.71 | 10.91 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $159,855,000.00 | $75,128,000.00 |
| Revenue This Year | $174.79 | N/A |
| Revenue Next Year | $66.73 | $21.85 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 162.95 | 160.56 |
| 52 Week Low | $16.00 | $2.75 |
| 52 Week High | $62.17 | $13.18 |
| Indicator | FLY | ABCL |
|---|---|---|
| Relative Strength Index (RSI) | 53.01 | 65.97 |
| Support Level | $21.17 | $10.38 |
| Resistance Level | $23.45 | N/A |
| Average True Range (ATR) | 1.32 | 0.61 |
| MACD | 0.16 | -0.01 |
| Stochastic Oscillator | 83.29 | 79.02 |
Firefly Aerospace Inc is a space and defense technology company with an established track record of success providing comprehensive mission solutions to national security, government, and commercial customers. The company develops and provides space and defense technologies, including launch vehicles and spacecraft systems, supporting launch, transit, and in-orbit operations for government, commercial, and national security customers. It has only one operating segment. The majority of the company's revenue is derived from Spacecraft Solutions.
AbCellera Biologics Inc is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody medicines for indications with high unmet medical need. It has built a platform for advancing antibody drug programs that the company believes provides it with a competitive advantage in addressing challenging, high-value targets such as complex transmembrane proteins and novel modalities, including multispecifics and antibody-drug conjugates. Organisation's pipeline includes two drug candidates in clinical development, two development candidates in Investigational New Drug (IND/Clinical Trial Application (CTA)-enabling activities, and more than 20 active discovery programs across multiple modalities and indications.